Literature DB >> 2324339

Clinical neurology and brain histopathology in NZB/NZW F1 lupus mice.

A B Kier1.   

Abstract

Active generalized systemic lupus erythematosus (SLE), clinical neurological deficits and histological lesions in the brains were present in New Zealand Black/New Zealand White (NZB/W) F1 mice at 10 to 18 months of age. Clinical neurological abnormalities of the central nervous system (CNS) were detected with a standardized neurological examination and scoring procedure. Active generalized SLE was present in all mice of this group, as determined by elevated serum anti-DNA antibodies and by the presence of glomerulonephritis. High titres of serum anti-cardiolipin antibodies were present in almost all mice. On histopathological examination, most of the brains had prominent mononuclear cell infiltration around cerebral and hippocampal blood vessels and in the choroid plexus. A subgroup of these mice, having higher clinical neurological scores, had correspondingly higher brain histopathological scores. The neurological and histological abnormalities were compatible with a diagnosis of CNS SLE. In contrast, 2-month-old NZB/W, 5-month-old C57Bl/6 and 14-month-old C57Bl/6 mice had low neurological scores, low serum anti-DNA antibody titres, low or absent anti-cardiolipin antibodies and no evidence of brain or kidney pathological lesions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2324339     DOI: 10.1016/s0021-9975(08)80122-3

Source DB:  PubMed          Journal:  J Comp Pathol        ISSN: 0021-9975            Impact factor:   1.311


  8 in total

1.  Selective cyclooxygenase-2 inhibitor suppresses renal thromboxane production but not proliferative lesions in the MRL/lpr murine model of lupus nephritis.

Authors:  Jim C Oates; Perry V Halushka; Florence N Hutchison; Philip Ruiz; Gary S Gilkeson
Journal:  Am J Med Sci       Date:  2011-02       Impact factor: 2.378

Review 2.  Cognitive Dysfunction in Systemic Lupus Erythematosus: A Case for Initiating Trials.

Authors:  Nina Kello; Erik Anderson; Betty Diamond
Journal:  Arthritis Rheumatol       Date:  2019-08-07       Impact factor: 10.995

Review 3.  Neuropsychiatric lupus: new mechanistic insights and future treatment directions.

Authors:  Noa Schwartz; Ariel D Stock; Chaim Putterman
Journal:  Nat Rev Rheumatol       Date:  2019-03       Impact factor: 20.543

4.  Lipocalin-2 is a pathogenic determinant and biomarker of neuropsychiatric lupus.

Authors:  Elise V Mike; Hadijat M Makinde; Maria Gulinello; Kamala Vanarsa; Leal Herlitz; Gaurav Gadhvi; Deborah R Winter; Chandra Mohan; John G Hanly; C C Mok; Carla M Cuda; Chaim Putterman
Journal:  J Autoimmun       Date:  2018-08-30       Impact factor: 7.094

5.  Antibody induction of lupus-like neuropsychiatric manifestations.

Authors:  David A Lawrence; Valerie J Bolivar; Chad A Hudson; Tapan K Mondal; Nina G Pabello
Journal:  J Neuroimmunol       Date:  2006-12-06       Impact factor: 3.478

6.  Hippocampal damage in mouse and human forms of systemic autoimmune disease.

Authors:  David A Ballok; John Woulfe; Monalisa Sur; Michael Cyr; Boris Sakic
Journal:  Hippocampus       Date:  2004       Impact factor: 3.899

Review 7.  New Zealand mixed mice: a genetic systemic lupus erythematosus model for assessing environmental effects.

Authors:  U H Rudofsky; D A Lawrence
Journal:  Environ Health Perspect       Date:  1999-10       Impact factor: 9.031

Review 8.  Lupus animal models and neuropsychiatric implications.

Authors:  Thaís Evelyn Karnopp; Gustavo Flores Chapacais; Eduarda Correa Freitas; Odirlei André Monticielo
Journal:  Clin Rheumatol       Date:  2020-11-06       Impact factor: 2.980

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.